Merck & Co Inc (MRK)

120.20 -1.00 (-0.83%)
Close EUR Disclaimer

Merck & Co Inc Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
71000
Equity Type
ORD
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Contact Information
Address
Rahway,07065 United States
Phone
908 740 4000
Fax
-
Top Executives
Name
Age
Since
Title
Christine E. Seidman 69 2020 Independent Director
Patricia F. Russo 70 1995 Independent Director
Inge G. Thulin 68 2018 Independent Director
Peter C. Wendell 71 2003 Independent Director
Stephen L. Mayo 60 2021 Independent Director
Thomas Henry Glocer 63 2007 Independent Lead Director
Paul B. Rothman 64 2015 Independent Director
Pamela J. Craig 65 2015 Independent Director
Mary Ellen Coe 54 2019 Independent Director
Risa J. Lavizzo-Mourey 67 2020 Independent Director
Douglas M. Baker 63 2022 Independent Director
Kathy J. Warden 50 2020 Independent Director
Robert M. Davis 55 2014 CEO & Chairman
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles